Search results
Biophytis grants Blanver Exclusive Rights to BIO101 in Latin America in Deal Valued at up to €108...
Digital Journal· 4 days agoPARIS, FRANCE AND CAMBRIDGE, MA / ACCESSWIRE / June 20, 2024 / Biophytis SA (Euronext Growth Paris:ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specialized ...
Newswise Expert | Anthony B. El-Khoueiry, Keck Medicine of USC
Newswise· 5 days agoDr. El-Khoueiry completed his medical degree, residency in internal medicine and fellowship in hematology and oncology at the Keck School of Medicine of the University of ...
What's Going On With Mustang Bio Stock Tuesday? - Mustang Bio (NASDAQ:MBIO)
Benzinga· 6 days agoMustang Bio is developing the treatment in collaboration with Fred Hutch Cancer Center. The data was presented at the European Hematology Association 2024 Hybrid Congress.
Newswise Expert | Heinz-Josef Lenz, Keck Medicine of USC
Newswise· 5 days agoHeinz-Josef Lenz, M.D., FACP, is the Associate Director for Clinical Research and Co-Leader of the Gastrointestinal Cancers Program at the USC Norris Comprehensive Cancer Center. Dr. Lenz is ...
Biophytis grants Blanver Exclusive Rights to BIO101 in Latin America in Deal Valued at up to €108...
StreetInsider· 4 days agoPARIS, FRANCE AND CAMBRIDGE, MA / ACCESSWIRE / June 20, 2024 / Biophytis SA (Euronext Growth Paris:ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specialized ...
Treatment of Blood Cancers
Digital Journal· 6 days agoVancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - June 18, 2024) - Investorideas.com, a go-to investing platform covering biotech and medical technology stocks releases the ...
June 2024 Insights Into Three Swedish Stocks Estimated Below Value
Simply Wall St. via Yahoo Finance· 4 days agoAmidst a backdrop of political uncertainty and fluctuating markets across Europe, Sweden's equities...
Oncology Mergers Are on the Rise. How Can Practices Survive?
Medscape· 5 days agoHow Can Independent Practices Survive? When he completed his fellowship at Fox Chase Cancer Center...
Reviews Cross-Journal Editorial Team
Nature· 4 days agoReviews Cross-Journal Editorial Team
M&A Is Back. 4 Stocks That Could Be Targets.
Barrons.com· 5 days agoMergers are back—and that means opportunity for small-cap investors. The return of M&A has been helped along by a number of factors, including a...